Home/ Stocks/ JSPR

Jasper Therapeutics, Inc. Common Stock

JSPR XNAS

$0.71 +0.06 (+9.89%) ▲ 15-min delayed

Open

$0.65

High

$0.75

Low

$0.65

Volume

759.5K

Market Cap

$21.50M

About Jasper Therapeutics, Inc. Common Stock

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 22 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-1,174,000	$-0.04
FY 2025	$0	$-75,801,000	$-3.95
Q3 2025	$0	$-18,736,000	$-1.13
Q1 2025	$0	$-21,241,000	$-1.41

Related Market News

No specific coverage for JSPR yet. Check out our latest market news or earnings calendar.

Get JSPR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Jasper Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.